$10.55 Million in Sales Expected for Theravance Biopharma Inc (TBPH) This Quarter

Share on StockTwits

Equities research analysts predict that Theravance Biopharma Inc (NASDAQ:TBPH) will post sales of $10.55 million for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Theravance Biopharma’s earnings. The highest sales estimate is $12.50 million and the lowest is $8.64 million. Theravance Biopharma reported sales of $4.28 million in the same quarter last year, which indicates a positive year-over-year growth rate of 146.5%. The company is expected to announce its next earnings results on Tuesday, November 6th.

According to Zacks, analysts expect that Theravance Biopharma will report full-year sales of $52.43 million for the current year, with estimates ranging from $49.30 million to $55.00 million. For the next financial year, analysts forecast that the business will post sales of $77.40 million per share, with estimates ranging from $44.99 million to $105.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that cover Theravance Biopharma.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Wednesday, August 1st. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($1.20) by $0.44. Theravance Biopharma had a negative return on equity of 261.70% and a negative net margin of 640.07%. The firm had revenue of $23.48 million during the quarter, compared to the consensus estimate of $9.97 million.

Several equities analysts recently weighed in on TBPH shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Theravance Biopharma in a research note on Wednesday, May 9th. Leerink Swann set a $31.00 price objective on Theravance Biopharma and gave the company a “buy” rating in a research note on Wednesday, May 9th. Cantor Fitzgerald set a $55.00 price objective on Theravance Biopharma and gave the company a “buy” rating in a research note on Tuesday, May 8th. ValuEngine raised Theravance Biopharma from a “hold” rating to a “buy” rating in a research note on Thursday, August 9th. Finally, BidaskClub raised Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Wednesday, May 30th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $40.00.

In other Theravance Biopharma news, EVP Bradford J. Shafer sold 10,140 shares of the firm’s stock in a transaction on Wednesday, June 6th. The stock was sold at an average price of $24.09, for a total transaction of $244,272.60. Following the completion of the transaction, the executive vice president now owns 133,324 shares of the company’s stock, valued at $3,211,775.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Renee D. Gala sold 43,743 shares of the firm’s stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $26.79, for a total value of $1,171,874.97. The disclosure for this sale can be found here. Insiders have sold 99,223 shares of company stock valued at $2,627,208 in the last three months. 6.90% of the stock is currently owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. Rhumbline Advisers increased its position in Theravance Biopharma by 4.6% during the second quarter. Rhumbline Advisers now owns 39,781 shares of the biopharmaceutical company’s stock worth $902,000 after buying an additional 1,757 shares in the last quarter. UBS Group AG boosted its holdings in shares of Theravance Biopharma by 88.4% during the first quarter. UBS Group AG now owns 4,511 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 2,117 shares during the last quarter. Royal Bank of Canada boosted its holdings in shares of Theravance Biopharma by 22.3% during the first quarter. Royal Bank of Canada now owns 16,664 shares of the biopharmaceutical company’s stock worth $404,000 after purchasing an additional 3,042 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its holdings in shares of Theravance Biopharma by 12.2% during the second quarter. State Board of Administration of Florida Retirement System now owns 28,578 shares of the biopharmaceutical company’s stock worth $648,000 after purchasing an additional 3,100 shares during the last quarter. Finally, Swiss National Bank boosted its holdings in shares of Theravance Biopharma by 5.3% during the first quarter. Swiss National Bank now owns 75,142 shares of the biopharmaceutical company’s stock worth $1,822,000 after purchasing an additional 3,800 shares during the last quarter. 85.66% of the stock is owned by institutional investors.

NASDAQ TBPH opened at $27.16 on Friday. Theravance Biopharma has a 1-year low of $21.27 and a 1-year high of $35.90. The company has a market capitalization of $1.54 billion, a P/E ratio of -4.98 and a beta of 1.80. The company has a quick ratio of 3.95, a current ratio of 4.14 and a debt-to-equity ratio of 6.52.

About Theravance Biopharma

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.

Further Reading: Outstanding Shares

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply